Latest close: back above its 200-day averageSep 8, 2026what changed →9/10Strongest Value, weakest Quality · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
Price
$31.13+103%1Y
1M+15%1Y+103%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierValue84
Quality34
Momentum79
Growth-
What they do
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
P/E (TTM)-
Market Cap$2.32B
1Y Return+103%
5Y Return-
Raw charts
5 series · TTMAs reported to the SEC, without any scoring.